People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Brainsway Ltd. | — | Biotechnology | Series B | $20.0M | $128.4M | 2024 |
| Silexion Therapeutics Corp | — | Biotechnology | Seed | $3.6M | $9.6M | 2025 |
Avner Lushi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Avner Lushi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ilan Hadar | 1 | 2 |
| Karen Sarid | 1 | 2 |
| Ruth Alon | 1 | 2 |
| Mitchell Shirvan | 1 | 1 |
| Shlomo Noy | 1 | 1 |
| Ilan Levin | 1 | 1 |
| Dror Abramov | 1 | 1 |
| Hadar Levy | 1 | 1 |
| Yossi Ben Shalom | 1 | 1 |
| Avner Hagai | 1 | 1 |
| David Zacut | 1 | 1 |
| Ido Marom | 1 | 1 |
| Abraham Zangen | 1 | 1 |
| Eti Mitrany | 1 | 1 |
| Ami Boehm | 1 | 1 |
| Mirit Horenshtein-Hadar | 1 | 1 |
| Amnon Peled | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.